Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.France-based biopharmaceutical company BioAlliance Pharma has reported encouraging results on its new biotherapy, plasmid AMEP, for metastatic melanoma treatment.
Subscribe to our email newsletter
BioAlliance Pharma said that plasmid AMEP displays anti-angiogenic and anti-metastatic properties. Results presented describe the anti-angiogenic and anti-tumoral properties of the plasmid AMEP biotherapy in in vitro and in vivo models, said BioAlliance Pharma.
In an in vivo experimental model of invasive melanoma, tumor treatment by plasmid AMEP biotherapy, applied through either intratumoral or intramuscular route, induced a strong tumor growth inhibition (>95% and >50%, respectively), according to the company. Moreover, preliminary acute toxicology studies show that plasmid AMEP biotherapy is safe and well-tolerated, the company added.
It is reported that preclinical toxicology and biodistribution regulatory studies are in progress and will allow the submission of the regulatory file for a Phase I clinical trial planned in 2009 in metastatic melanoma patients.